75F40121C00111

CONTROLLED PROTEIN CAPTURE VIA CONTINUOUS CRYSTALLIZATION AND PRECIPITATION FOR MONOCLONAL ANTIBODY MANUFACTURING - BAA PMQWP 324

Award details

Obligations, current value and potential value describe different measures; they are never added together.

Field	Reported value
Agency	Department of Health and Human Services
Office	FDA OFFICE OF ACQ GRANT SVCS
NAICS	541714 — Research and Development in Biotechnology (except Nanobiotechnology)
PSC	AN11 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH
Parent award / vehicle	Not reported
Set-aside	NO SET ASIDE USED.
Pricing type	COST NO FEE
Obligations	$5.0M
Current contract value	$5.0M
Potential contract value / ceiling	$5.0M
Start date	Aug 20, 2021
Current end date	Aug 31, 2025
Potential end date	Aug 31, 2025
Latest award activity	Jul 23, 2025
Source loaded	Sep 26, 2026

Showing the latest 7 of 7 loaded transactions. Negative values are deobligations.

Date	Modification	Obligation change	Description
Jul 23, 2025	P00006	$0	CONTROLLED PROTEIN CAPTURE VIA CONTINUOUS CRYSTALLIZATION AND PRECIPITATION FOR MONOCLONAL ANTIBODY MANUFACTURING - BAA PMQWP 324 - CO/BUYER CHANGE
Jun 12, 2025	P00005	$0	NCE DUE TO STAFFING AND SUPPLY ISSUES
Aug 2, 2024	P00004	$0	NCE DUE TO STAFFING AND SUPPLY ISSUES
Jul 20, 2023	P00003	$1.4M	CONTROLLED PROTEIN CAPTURE VIA CONTINUOUS CRYSTALLIZATION AND PRECIPITATION FOR MONOCLONAL ANTIBODY MANUFACTURING - BAA PMQWP 324
Apr 15, 2022	P00002	$0	INCORPORATION OF HHSAR 352.232-71, ELECTRONIC SUBMISSION OF PAYMENT REQUESTS (FEB 2022) AND FDA ELECTRONIC INVOICING AND PAYMENT REQUIREMENTS - INVOICE PROCESSING PLATFORM (IPP) (JAN 2022).
Dec 1, 2021	P00001	$0	EO14042 CONTROLLED PROTEIN CAPTURE VIA CONTINUOUS CRYSTALLIZATION AND PRECIPITATION FOR MONOCLONAL ANTIBODY MANUFACTURING - BAA PMQWP 324
Aug 20, 2021	0	$3.6M	CONTROLLED PROTEIN CAPTURE VIA CONTINUOUS CRYSTALLIZATION AND PRECIPITATION FOR MONOCLONAL ANTIBODY MANUFACTURING - BAA PMQWP 324